The ITP Channel

Explore the latest updates and expert interviews

Welcome to The Immune Thrombocytopenia (ITP) Channel

Keep up to date with the most recent diagnosis, treatment, and management developments in immune thrombocytopenia (ITP). Reporting from major international congresses, VJHemOnc brings you exclusive and informative video interviews with world-leading experts in the field.

Long-term risks associated with persistent isolated mild thrombocytopenia 3:15
Long-term risks associated with persistent isolated mild thrombocytopenia
Hanny Al-Samkari • 24 Apr 2023
Fostamatinib and efgartigimod: novel agents in the treatment of ITP 1:53
Fostamatinib and efgartigimod: novel agents in the treatment of ITP
Nichola Cooper • 27 Apr 2023
Session overview: pitfalls in the diagnosis of bleeding disorders & research networks in the UK 1:59
Session overview: pitfalls in the diagnosis of bleeding disorders & research networks in the UK
Gillian Lowe • 28 Apr 2023
Session overview: improving treatment for patients with ITP 3:23
Session overview: improving treatment for patients with ITP
Nichola Cooper • 27 Apr 2023
Chemotherapy-induced thrombocytopenia: shifting treatment strategies and the use of TPOR agonists 2:43
Chemotherapy-induced thrombocytopenia: shifting treatment strategies and the use of TPOR agonists
Hanny Al-Samkari • 24 Apr 2023
Shifting the treatment landscape of ITP: novel agents and future outlooks 1:32
Shifting the treatment landscape of ITP: novel agents and future outlooks
David Kuter • 24 Apr 2023
The role and clinical use of TPO receptor agonists in the treatment of ITP 0:52
The role and clinical use of TPO receptor agonists in the treatment of ITP
David Kuter • 24 Apr 2023
Rilzabrutinib: a novel promising BTK inhibitor being explored in ITP 0:52
Rilzabrutinib: a novel promising BTK inhibitor being explored in ITP
David Kuter • 24 Apr 2023
Thrombopoietin receptor agonists in ITP: current status and future outlooks 3:17
Thrombopoietin receptor agonists in ITP: current status and future outlooks
Hanny Al-Samkari • 24 Apr 2023
Continuous IVIG and platelet transfusion for refractory AITP in patients undergoing alloSCT 2:09
Continuous IVIG and platelet transfusion for refractory AITP in patients undergoing alloSCT
Muhammad Umair Mushtaq • 17 Feb 2023
Impact of obesity on outcomes in patients with primary ITP 1:45
Impact of obesity on outcomes in patients with primary ITP
Irina Murakhovskaya • 12 Dec 2022
Outcomes of patients with CLL-associated autoimmune cytopenias treated with different therapies 1:21
Outcomes of patients with CLL-associated autoimmune cytopenias treated with different therapies
Kerry Rogers • 12 Dec 2022
Novel promising agents for the treatment of ITP 1:29
Novel promising agents for the treatment of ITP
Hanny Al-Samkari • 11 Dec 2022
ADVANCE IV results: efficacy and safety of intravenous efgartigimod in adults with primary ITP 5:45
ADVANCE IV results: efficacy and safety of intravenous efgartigimod in adults with primary ITP
Catherine Broome • 10 Dec 2022
Insights from ADVANCE IV study: efgartigimod increases platelet counts of patients with ITP 0:52
Insights from ADVANCE IV study: efgartigimod increases platelet counts of patients with ITP
Catherine Broome • 12 Dec 2022
Anemia, bilirubin, and LDH identified as indicators of an increased mortality risk in CAD 1:15
Anemia, bilirubin, and LDH identified as indicators of an increased mortality risk in CAD
Catherine Broome • 12 Dec 2022

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals